Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017
March 06, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
January 26, 2017 10:51 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
January 11, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event
November 21, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it will be presenting at the 9th annual LD Micro Main Event...
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016
November 14, 2016 16:36 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announces the filing of its Quarterly Report and its financial results for the nine months ended September 30, 2016....
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016
November 10, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial...
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”
November 08, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on...
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME
October 31, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Data presented at the 12th...
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
October 19, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it has completed its technology transfer of the Ampligen®...
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards
September 19, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company”), announced today that, based on a notice received on September 15, 2016 from the New York Stock...